Exclusive Industry Content 2026

When you’re managing external manufacturing today, the pressure isn’t abstract; it’s daily, immediate, and growing. Capacity is tightening across sterile and biologics, global regulations are shifting faster than contracts can keep up, and geopolitical instability is reshaping where medicines can be made, sourced, and shipped.

This is exactly why the 2026 Pharma Contract Manufacturing Market Report was built: to give you the clarity, the benchmarks, and the competitive intelligence you need to make confident decisions in a market that isn’t standing still.

With expert commentary from Christian Simon, Head of Technical Transfer, External Manufacturing, Sanofi, and Philip Coetzee, Director, CMO Management, Daiichi Sankyo, they both share their insights on how to deliver reliability with less buffer, innovation with fewer resources, and agility with partners facing the same constraints you are.

Download to learn more about:

• Market Shifts You Need to Know: The global CMO/CDMO market is accelerating toward $319.6B by 2029, with biotech outsourcing growing more than 12% year-on-year.
• Risks You’re Navigating Every Day: Supply chain disruptions have increased by 38% in the past 12 months, driven by tariffs, sanctions, and regional realignments.
• What Makes Partnerships Actually Work in 2026: Strong alliances are built on shared visibility, structured communication, and joint planning, not just SLAs. Pharma teams that implement integrated review cycles with CMOs report 20-30% fewer delays and higher tech-transfer success.
• Innovation You Can’t Afford to Ignore: Digital twins and AI-based planning are improving cycle time by 15-40% in organisations already adopting them. Single-use systems continue to gain ground, reducing cleaning-related downtime by up to 60%.

If you’re operating in an environment where a single disruption – a delayed material, a missed forecast, an unexpected deviation – can ripple across your entire supply network. This report gives you the insights to anticipate those pressures, benchmark your partnerships, and build agility into your operations before the next disruption hits. Equip yourself with the intelligence to strengthen your CMO/CDMO relationships, negotiate with confidence, and protect your supply chain in the year ahead.

Download your copy now and stay ahead of the pressures reshaping pharma contract manufacturing.

If you’re managing external manufacturing today, technology is already shaping your risk, your timelines, and your relationships with CMOs and CDMOs. Digital maturity gaps, uneven automation, and rising regulatory expectations mean that how your partners invest in technology now directly impacts supply resilience and quality outcomes.

This technology report gives you a clear view of how smart manufacturing, AI, automation, and digital quality systems are reshaping pharma contract manufacturing, and what this means for your CMO strategy in the year ahead.

Download this report to understand:

• Which manufacturing technologies are genuinely improving reliability, compliance, and capacity
• How digitalisation is changing pharma–CMO collaboration, visibility, and decision-making
• Where technology gaps in your supply network could become future risk     

This report sets the context for the conversations happening at Pharma Contract Manufacturing 2026 (23–25 March, Berlin), where pharma and CMO leaders will go deeper into how technology, partnerships, and capacity planning must evolve together under pressure.

Download the report now, and come to PCM 2026 ready to challenge assumptions, benchmark your partners, and engage in more informed, practical discussions with your manufacturing network.

When you’re a mid-sized pharma or biotech company, external manufacturing isn’t a support function – it is your supply chain.

You don’t have excess capacity to fall back on. You don’t have teams dedicated solely to benchmarking suppliers or rewriting quality agreements every time regulations shift. Yet you’re expected to deliver the same reliability, compliance, and speed as companies many times your size, often in a market defined by tight capacity, rising costs, and geopolitical uncertainty.

This How-To Guide was created for organisations like yours. It brings together practical frameworks for benchmarking CMO/CDMO performance, guidance on quality agreements that actually drive accountability, real-world strategies for moving partnerships from fragile to agile, without adding unnecessary complexity or bureaucracy, and expert commentary from Tero Virtanen, Sourcing Manager, Orion Corporation.

Written with the realities of mid-sized pharma and biotech teams in mind, this guide focuses on what you can control: visibility, expectations, digital maturity, and partnership design.

Download to learn how to:

• Benchmark CMO/CDMO performance with confidence, using metrics that reflect today’s capacity, quality, and digital realities
• Draft and negotiate quality agreements that protect supply and accountability, not just legal positions
• Build agile partnerships that can absorb shocks, from regulatory change to material shortages and geopolitical disruption

If your growth, pipeline, or patient access depends on external manufacturers – and you can’t afford surprises – this guide gives you the structure, language, and tools to strengthen your partnerships before pressure turns into risk.

Download the guidebook now and take control of your CMO performance in 2026.